18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma

Neuroblastoma Clinical Trial

Official title:

18F-mFBG LAFOV PET/CT Compared to 123I-mIBG Scintigraphy SPECT/CT for Evaluation of Children With Neuroblastoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05826158
• Other study ID #: j. nr. H-21009982_v3
• Status: Recruiting
• Phase: Phase 3
• Start date: June 6, 2022
• Est. completion date: December 31, 2025

Study information

• Verified date: April 2023
• Source: Rigshospitalet, Denmark
• Contact: Lise Borgwardt, MD, PhD.
• Phone: +4535459568
• Email: lise.borgwardt[@]regionh.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a study evaluating the positron-emitting radiopharmaceutical 18F-mFBG compared to 123I-mIBG scintigraphy for imaging of neuroblastoma

Description:

This is a prospective study designed to assess the use of 18F-mFBG PET imaging compared to 123I-mIBG scintigraphy in subjects with known or presumed neuroblastoma. Eligible participants will have either histopathologically established diagnosis of neuroblastoma or a presumed diagnosis based on signs, symptoms, physical examination, imaging findings, and laboratory and genetic test results.

Subjects will only be administered 18F-mFBG if they have undergone or are scheduled to undergo a 123I-mIBG within +/- 7 days of the date of the 18F-mFBG scan. Subjects should not have received any chemotherapy, immunotherapy or radiotherapy between the clinical and 18F-mFBG imaging studies.

18F-mFBG PET studies will be evaluated by 2 independent teams of blinded readers: a nuclear medicine physician and a radiologist, both specialized in pediatric nuclear medicine co-reading side-by side.

The clinical 123I-mIBG is also evaluated by 2 independent teams of blinded readers: a nuclear medicine physician and a radiologist, both specialized in pediatric nuclear medicine co-reading side-by side.

Blinded readers will record whether findings on 18F-mFBG and 123I-mIBG scans are consistent with neuroblastoma.

Subject-level diagnostic performance will be assessed on the basis of differencies in lesion-counting between the blinded 18F-mFBG scan interpretation and the 123I-mIBG scan. In case of discrepancy, independently assessed by an Expert Panel.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 25
• Est. completion date: December 31, 2025
• Est. primary completion date: September 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 18 Years

Eligibility

Inclusion Criteria:

1. An established diagnosis of neuroblastoma based on unequivocal histopathology from tissue obtained at any time prior to enrolment in the trial; OR b) A presumed diagnosis of neuroblastoma based on signs, symptoms, physical examination, imaging findings, and laboratory and genetic test results, including individuals in whom therapy has already been empirically initiated.

2. The subject has undergone or is scheduled to undergo evaluation of neuroblastoma disease status, including 123I-mIBG +/- 7 days to the date of 18F-mFBG imaging, with no therapy between such evaluation.

3. Ability of subject or subject's legal guardian to understand and sign a written informed consent document.

-

Exclusion Criteria:

1. Pregnancy

-

Related Conditions & MeSH terms

• Neuroblastoma

Intervention

Diagnostic Test:
• 18FmFBG imaging on the Large Field of View PET/CT (Total body PET/CT)
18F-mFBG imaging on the Large Field of View PET/CT (Total body PET/CT)

Locations

Country	Name	City	State
Denmark	Rigshospitalet, Copenhagen University Hospital	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	18F-mFBG PET Scan identification of Neuroblastoma on the LAFOV PET/CT	Pathological 18F-mFBG uptake when imaging after 60 minutes with LAFOV PET/CT	60 minutes
Secondary	Comparison of 18F-mFBG with Clinical 123I-mIBG imaging	Pathological uptake on 18F-mFBG will be compared with pathological uptake on 123I-mIBG, lesions based comparison	7 days apart